AVROBIO INC's ticker is AVRO and the CUSIP is 05455M100. A total of 101 filers reported holding AVROBIO INC in Q1 2021. The put-call ratio across all filers is 0.36 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,860 | +62.2% | 1,208 | 0.0% | 0.00% | – |
| Q2 2023 | $1,147 | -98.1% | 1,208 | -97.4% | 0.00% | – |
| Q1 2022 | $61,000 | -69.0% | 46,582 | -9.1% | 0.00% | – |
| Q4 2021 | $197,000 | -32.1% | 51,260 | -1.3% | 0.00% | – |
| Q3 2021 | $290,000 | -34.7% | 51,950 | +4.0% | 0.00% | -100.0% |
| Q2 2021 | $444,000 | -5.5% | 49,930 | +34.8% | 0.00% | 0.0% |
| Q1 2021 | $470,000 | -11.2% | 37,033 | -2.5% | 0.00% | 0.0% |
| Q4 2020 | $529,000 | +13.8% | 37,983 | +6.4% | 0.00% | 0.0% |
| Q3 2020 | $465,000 | -32.7% | 35,693 | -9.8% | 0.00% | 0.0% |
| Q2 2020 | $691,000 | +80.9% | 39,577 | +61.3% | 0.00% | 0.0% |
| Q1 2020 | $382,000 | -13.6% | 24,530 | +11.7% | 0.00% | 0.0% |
| Q4 2019 | $442,000 | +49.8% | 21,967 | +5.1% | 0.00% | 0.0% |
| Q3 2019 | $295,000 | -1.0% | 20,894 | +14.0% | 0.00% | 0.0% |
| Q2 2019 | $298,000 | +0.7% | 18,326 | +36.5% | 0.00% | 0.0% |
| Q1 2019 | $296,000 | +26.0% | 13,422 | +196.1% | 0.00% | – |
| Q3 2018 | $235,000 | – | 4,533 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Atlas Venture Life Science Advisors, LLC | 4,520,863 | $5,968,000 | 0.76% |
| Aisling Capital Management LP | 1,009,779 | $1,333,000 | 0.72% |
| MPM BioImpact LLC | 647,918 | $855,000 | 0.23% |
| GMT CAPITAL CORP | 2,594,914 | $3,425,000 | 0.22% |
| New Leaf Venture Partners, L.L.C. | 315,550 | $417,000 | 0.21% |
| GSA CAPITAL PARTNERS LLP | 338,422 | $447,000 | 0.06% |
| Penn Mutual Asset Management, LLC | 37,306 | $49,000 | 0.06% |
| Eversept Partners, LP | 295,369 | $389,887 | 0.03% |
| XTX Topco Ltd | 23,289 | $31,000 | 0.01% |
| Colonial River Wealth Management, LLC | 17,636 | $23,000 | 0.01% |